Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013089790> ?p ?o ?g. }
- W2013089790 endingPage "3651" @default.
- W2013089790 startingPage "3644" @default.
- W2013089790 abstract "The CB(2) receptor activation can be exploited for the treatment of diseases such as chronic pain and tumors of immune origin, devoid of psychotropic activity. On the basis of our already reported 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives, new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the human CB(1) and CB(2) cannabinoid receptors. Some of the reported compounds showed a subnanomolar CB(2) affinity with a CB(1)/CB(2) selectivity ratio greater than 200 (compounds 6, 12, cis-12, 13, and cis-13). Further studies revealed that compound 12, which presented benzyl and carboxy-4-methylcyclohexylamide substituents bound in the 1 and 3 positions, exerted a CB(2)-mediated inhibitory action on immunological human basophil activation. On the human T cell leukemia line Jurkat the same derivative induced a concentration-dependent decrease of cell viability. The obtained results suggest that 1,8-naphthyridin-2(1H)-on-3-carboxamides represent a new scaffold very suitable for the development of new promising CB(2) agonists." @default.
- W2013089790 created "2016-06-24" @default.
- W2013089790 creator A5003958577 @default.
- W2013089790 creator A5007484138 @default.
- W2013089790 creator A5010742011 @default.
- W2013089790 creator A5012817716 @default.
- W2013089790 creator A5013014262 @default.
- W2013089790 creator A5014487066 @default.
- W2013089790 creator A5042182278 @default.
- W2013089790 creator A5050731923 @default.
- W2013089790 creator A5064184638 @default.
- W2013089790 creator A5067132089 @default.
- W2013089790 creator A5068513157 @default.
- W2013089790 creator A5081576364 @default.
- W2013089790 creator A5084587144 @default.
- W2013089790 date "2009-05-12" @default.
- W2013089790 modified "2023-09-27" @default.
- W2013089790 title "Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1<i>H</i>)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists" @default.
- W2013089790 cites W1833104430 @default.
- W2013089790 cites W1964037009 @default.
- W2013089790 cites W1964323384 @default.
- W2013089790 cites W1965729736 @default.
- W2013089790 cites W1966590801 @default.
- W2013089790 cites W1968547119 @default.
- W2013089790 cites W1979829009 @default.
- W2013089790 cites W1981189830 @default.
- W2013089790 cites W1988800581 @default.
- W2013089790 cites W1998141662 @default.
- W2013089790 cites W2002755329 @default.
- W2013089790 cites W2002935274 @default.
- W2013089790 cites W2005074057 @default.
- W2013089790 cites W2028794471 @default.
- W2013089790 cites W2032178587 @default.
- W2013089790 cites W2033771931 @default.
- W2013089790 cites W2036963690 @default.
- W2013089790 cites W2043884829 @default.
- W2013089790 cites W2059749815 @default.
- W2013089790 cites W2063727131 @default.
- W2013089790 cites W2071014521 @default.
- W2013089790 cites W2074631079 @default.
- W2013089790 cites W2075186867 @default.
- W2013089790 cites W2077481637 @default.
- W2013089790 cites W2083020065 @default.
- W2013089790 cites W2122168089 @default.
- W2013089790 cites W2136160086 @default.
- W2013089790 cites W2152636349 @default.
- W2013089790 cites W2158443507 @default.
- W2013089790 cites W2170404525 @default.
- W2013089790 cites W291278653 @default.
- W2013089790 doi "https://doi.org/10.1021/jm801563d" @default.
- W2013089790 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19435366" @default.
- W2013089790 hasPublicationYear "2009" @default.
- W2013089790 type Work @default.
- W2013089790 sameAs 2013089790 @default.
- W2013089790 citedByCount "35" @default.
- W2013089790 countsByYear W20130897902012 @default.
- W2013089790 countsByYear W20130897902013 @default.
- W2013089790 countsByYear W20130897902014 @default.
- W2013089790 countsByYear W20130897902015 @default.
- W2013089790 countsByYear W20130897902016 @default.
- W2013089790 countsByYear W20130897902017 @default.
- W2013089790 countsByYear W20130897902018 @default.
- W2013089790 countsByYear W20130897902019 @default.
- W2013089790 countsByYear W20130897902020 @default.
- W2013089790 countsByYear W20130897902021 @default.
- W2013089790 countsByYear W20130897902022 @default.
- W2013089790 countsByYear W20130897902023 @default.
- W2013089790 crossrefType "journal-article" @default.
- W2013089790 hasAuthorship W2013089790A5003958577 @default.
- W2013089790 hasAuthorship W2013089790A5007484138 @default.
- W2013089790 hasAuthorship W2013089790A5010742011 @default.
- W2013089790 hasAuthorship W2013089790A5012817716 @default.
- W2013089790 hasAuthorship W2013089790A5013014262 @default.
- W2013089790 hasAuthorship W2013089790A5014487066 @default.
- W2013089790 hasAuthorship W2013089790A5042182278 @default.
- W2013089790 hasAuthorship W2013089790A5050731923 @default.
- W2013089790 hasAuthorship W2013089790A5064184638 @default.
- W2013089790 hasAuthorship W2013089790A5067132089 @default.
- W2013089790 hasAuthorship W2013089790A5068513157 @default.
- W2013089790 hasAuthorship W2013089790A5081576364 @default.
- W2013089790 hasAuthorship W2013089790A5084587144 @default.
- W2013089790 hasConcept C148001335 @default.
- W2013089790 hasConcept C170493617 @default.
- W2013089790 hasConcept C179464577 @default.
- W2013089790 hasConcept C185592680 @default.
- W2013089790 hasConcept C203014093 @default.
- W2013089790 hasConcept C2776090121 @default.
- W2013089790 hasConcept C2778327999 @default.
- W2013089790 hasConcept C2778938600 @default.
- W2013089790 hasConcept C2780871563 @default.
- W2013089790 hasConcept C55493867 @default.
- W2013089790 hasConcept C71240020 @default.
- W2013089790 hasConcept C71924100 @default.
- W2013089790 hasConcept C86803240 @default.
- W2013089790 hasConcept C8891405 @default.
- W2013089790 hasConcept C98274493 @default.
- W2013089790 hasConceptScore W2013089790C148001335 @default.
- W2013089790 hasConceptScore W2013089790C170493617 @default.